Previous 10 | Next 10 |
Ionis expands eplontersen agreement with AstraZeneca to include exclusive rights in Latin America PR Newswire Companies jointly developing and commercializing eplontersen in the U.S. AstraZeneca adds Latin America as part of its exclusive rights for rest of wor...
Ionis to hold second quarter 2023 financial results webcast PR Newswire Webcast scheduled for Wednesday, August 9 at 11:30 a.m. Eastern Time CARLSBAD, Calif. , July 26, 2023 /PRNewswire/ -- Ionis Pharmaceuticals, Inc. (Nasdaq: IONS) announced toda...
Eplontersen continued to show improvement in ATTRv-PN through 85 weeks PR Newswire Topline Phase 3 NEURO-TTRansform results show eplontersen continued to halt neuropathy disease progression and improve quality of life through 85 weeks Data further strengthen eplonter...
2023-07-07 15:00:36 ET Welcome to Seeking Alpha's Catalyst Watch - a breakdown of some of next week's actionable events that stand out. Check out Saturday morning's regular Stocks to Watch article for a full list of events planned for the week, or the Seeking Alpha earnings calendar ...
Ionis to present at upcoming investor conference PR Newswire CARLSBAD, Calif. , July 5, 2023 /PRNewswire/ -- Ionis Pharmaceuticals, Inc. (Nasdaq: IONS) today announced that management will participate in a fireside chat at TD Cowen's 2nd Annual RNA Therapeutics S...
New data highlight potential benefit of SPINRAZA® (nusinersen) in infants and toddlers with unmet medical needs after gene therapy PR Newswire Interim results from RESPOND study show improved motor function in most participants treated with SPINRAZA after Zolgensma...
Interim results from the RESPOND study show improved motor function in most participants treated with SPINRAZA after Zolgensma ® (onasemnogene abeparvovec) Biogen also reported new real-world evidence and progress on the development of a novel device to enhance the patient treatm...
2023-06-20 06:58:24 ET Summary Ionis Pharmaceuticals' phase 2 study showed that patients treated with donidalorsen through week 17 achieved a 90% reduction in hereditary angioedema attack compared to placebo; the second dose brought a 97% reduction. Clinical trial results from the...
2023-06-08 03:57:44 ET Ionis Pharmaceuticals ( NASDAQ: IONS ) prices $500M aggregate principal amount of 1.75% convertible senior notes due 2028 in a private placement to qualified institutional buyers. The initial purchasers are granted an option to purchase, within the 13-...
2023-06-07 12:02:37 ET Major market averages were seeking direction during Wednesday's midday session ahead of CPI data and the Fed's policy meeting next week. Tracking individual stocks, Stitch Fix ( NASDAQ: SFIX ) shares rose and Casey's General Stores ( NASDAQ: CASY )...
News, Short Squeeze, Breakout and More Instantly...
Ionis Pharmaceuticals Inc. Company Name:
IONS Stock Symbol:
NASDAQ Market:
Ionis Pharmaceuticals Inc. Website:
Ionis announces positive detailed results from the HALOS Study of ION582 in people with Angelman syndrome PR Newswire ION582 showed robust and consistent benefit in communication, cognition and motor function in a broad patient population evaluated with a comprehensive set o...
Ionis to hold second quarter 2024 financial results webcast PR Newswire Webcast scheduled for Thursday, August 1 at 11:30 a.m. Eastern Time CARLSBAD, Calif. , July 19, 2024 /PRNewswire/ -- Ionis Pharmaceuticals, Inc. (Nasdaq: IONS) announced ...
Ionis completes enrollment in pivotal trial evaluating zilganersen in people living with Alexander disease PR Newswire Zilganersen is the first investigational medicine in clinical development for people with Alexander disease, a rare, life-threatening neurological condition...